- Home
- ALLO vs WDI Comparison
ALLO vs WDI Comparison
Compare ALLO & WDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALLO | WDI |
|---|---|---|
| Founded | 2017 | 2021 |
| Country | United States | United States |
| Employees | 152 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.1M | 715.3M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALLO | WDI |
|---|---|---|
| Price | $2.09 | $12.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $8.35 | N/A |
| AVG Volume (30 Days) | ★ 5.9M | 214.8K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.80% |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ 1.12 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $142,416.42 | N/A |
| P/E Ratio | ★ N/A | $11.58 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $12.91 |
| 52 Week High | $4.46 | $15.28 |
Technical Indicators
Market Signals| Indicator | ALLO | WDI |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 32.66 |
| Support Level | $2.07 | N/A |
| Resistance Level | $2.25 | $13.86 |
| Average True Range (ATR) | 0.11 | 0.12 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 65.85 | 10.00 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income. As a secondary investment objective, the Fund will seek capital appreciation. The fund seeks to achieve its investment objectives by investing, under normal market conditions, across fixed income sectors and securities in seeking to deliver a well-diversified portfolio.